Weight Loss / Dual incretin
Microdose tirzepatide
CompoundedThis tirzepatide pathway uses compounded medicine at clinician-controlled low doses. A clinician assesses whether treatment is appropriate and selects any patient-specific preparation and dose. Tirzepatide acts on GIP and GLP-1 receptors involved in appetite and food intake. “Microdose” is not a standardized FDA-approved regimen or a promise of fewer side effects; do not infer a dose or schedule from this name or change treatment without clinical direction.
Online enrollment opens soon.
- Adults 18 and older
- Eligibility depends on your location and health history
- Not available to patients covered by Medicare, Medicaid or TRICARE
- A completed review does not guarantee a prescription
Compounded medication
Compounded medicines are not FDA approved. FDA does not assess their safety, effectiveness or quality before marketing. They are not FDA-approved generics or interchangeable substitutes for approved medicines. A clinician must determine whether a compounded preparation is appropriate; the pharmacy is responsible for its preparation and labeling. Packaging shown is illustrative; the dispensed product may look different. This medicine is available only after an online evaluation and a prescription from a licensed clinician, if appropriate.
Important safety information
The risks and contraindications of tirzepatide still matter when a smaller dose is considered; a smaller dose is not a safety guarantee. Discuss pregnancy, other medicines, and personal or family history of medullary thyroid carcinoma or MEN 2 with the clinician. Not for emergencies: call 911.
Billing, cancellation and refunds: Terms & Conditions · Returns, Refunds & Cancellation · Consent to Telehealth